Influence of granulocyte-macrophage colony-stimulating factor (GM-CSF) on whole blood endotoxin responsiveness following trauma, cardiopulmonary bypass, and severe sepsis

Shock

Volumn 12, Issue 1, 1999, Pages 17-24

  Flohé, Sascha ^a   Börgermann, Jochen ^a   Domínguez, Fernández Emilio ^a   Majetschak, Matthias ^a   Lim, Lucy ^a   Kreuzfelder, Ernst ^a   Obertacke, Udo ^a   Nast Kolb, Dieter ^a   Schade, Fritz Ulrich ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Hematopoetic growth factors; HLA DR expression; Immunoincompetence; Lipopolysaccharides; TNF

Indexed keywords

ENDOTOXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 10; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; BLOOD CELL; CARDIOPULMONARY BYPASS; CELL CULTURE; FEMALE; HUMAN; IMMUNOLOGY; INJURY; MALE; METABOLISM; MIDDLE AGED; SEPTIC SHOCK;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD CELLS; CARDIOPULMONARY BYPASS; CELLS, CULTURED; DINOPROSTONE; ENDOTOXINS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; SHOCK, SEPTIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA; WOUNDS AND INJURIES;

EID: 0033159622     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199907000-00003     Document Type: Article

References (43)

1. Bone RC: Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 24:163-172, 1996.
2. Hack CE, Aarden LA, Thijs LG: Role of cytokines in sepsis. Adv Immunol 66:101-195, 1997.
3. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, et al.: Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273:934-941, 1995.
4. Fischer CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E: Treatment of septic shock with the tumor necrosis factor/Fc fusion protein. N Engl J Med 334:1697-1702, 1996.
5. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, Wiegemann K, Ohashi PS, Kronke M, Mak TW: Mice deficient for the 55kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73:457-467, 1993.
6. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak TW, Blom BR: Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561-572, 1995.
7. Taffet SM, Eurell TE, Russel SW: Regulation of macrophage-mediated tumor cell killing by prostaglandins: comparison of the effects of PGE2 and PGI2. Prostaglandins 24:763-774, 1982.
8. Fiorentino DF, Zlotnik A, Mosman TR, Howard M, O'Garra A: IL-10 inhibits cytokine production by activated macrophages. J Immunol 147: 3815-3822, 1991.
9. Marchant A, Alegre ML, Hakim A, Pierard G, Marecaux G, Friedman G, de Groote D, Kahn RJ, Vincent JL, Goldman M: Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J Clin Immunol 15:266-273, 1995.
10. Volk HD, Thieme M, Heym S, Docke WD, Ruppe U, Tausch W, Manger D, Zuckermann S, Golosubow A, Nieter B, et al.: Alterations in function and phenotype of monocytes from patients with septic disease: predictive value and new therapeutic strategies. Behring Inst Mitt 208-215, 1991.
11. Keel M, Schregenberger N, Streckholzer U, Ungethum U, Kenney J, Trentz O, Ertel W: Endotoxin tolerance after severe injury and its regulatory mechanisms. J Trauma 41(3):430-443, 1996.
12. Munoz C, Carlet J, Fitting C, Misset B, Blériot JP, and Cavaillon JM: Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 88:1747-1754, 1991.
13. Ertel W, Kremer JP, Kenney J, Steckholzer U, Jarrar D, Trentz O, Schildberg FW: Downregulation of proinflammatory cytokine release in whole blood from sepsis patients. Blood 85:1341-1347, 1995.
14. Majetschak M, Flach R, Jennissen V, Kreuzfelder E, Heukamp T, Neudeck F, Obertacke U, Schmit-Neuerburg KP, Schade FU: The extent of traumatic damage determines a graded depression of the endotoxin responsiveness of peripheral mononuclear cells from patients with blunt trauma. Crit Care Med, 1998 in press.
15. Rapoport AP, Abboud CN, DiPersio JF: Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF): receptor biology, signal transduction, and neutrophil activation. Blood Rev 6:43-57, 1992.
16. Hayes MP, Freeman SL, Donnelly RP: IFNγ priming of monocytes enhances LPS-induced TNF production by augmenting both transcription and MRNA stability. Cytokine 7:427-435, 1995.
17. Williams MA, Kelsey SM, Collins PW, Gutteridge CN, Newland AC: Administration of rHuGM-CSF activates monocyte reactive oxygen species secretion and adhesion molecule expression in vivo in patients following high-dose chemotherapy. Br J Haematol 90:31-40, 1995.
18. 4 synthesis. J Immunol 140:4315-4322, 1988.
19. Sullivan R, Griffin JD, Simons ER, Schafer AI, Meshulam T, Fredette JP, Maas AK, Gadenne A, Leavitt JL, Melnick DA: Effects of recombinant human Granulocyte and Macrophage Colony-Stimulating Factors on signal transduction pathways in human granulocytes. J Immunol 139:3422-3430, 1987.
20. Randow F, Döcke WD, Bundschuh DS, Hartung T, Wendel A, and Volk HD: In vitro prevention and reversal of lipopolysaccharide desensitization by IFNγ, IL-12, and granulocyte-macrophage colony-stimulating factor. J Immunol 158:2911-2918, 1997.
21. Lieschke GJ, Burgees AW: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 327:28-35, 1992.
22. Baker SP, O'Neill B, Haddon W, Long W: The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma 14:187-196, 1974.
23. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655, 1992.
24. Goris RJA, Draaisma J: Causes of death after blunt trauma. J Trauma 22:141-146, 1982.
25. Keel M, Schregenberger N, Steckholzer U, Ungethum U, Kenney J, Trentz O, Ertel W: Endotoxin tolerance after severe injury and its regulatory mechanisms. J Trauma 41:430-437, 1996.
26. Fabian TC, Croce MA, Fabian MJ, Trenthem LL, Yockey JM, Boscarino R, Proctor KG: Reduced tumor necrosis factor production in endotoxin-spiked whole blood after trauma: experimental results and clinical correlation. Surgery 118:63-72, 1995.
27. Misoph M, Babin-Ebell J, Schwender S, Grossmann R, Keller F, Elert O: Response of the cellular immune system to cardiopulmonary bypass in vivo. Thorac Cardiovasc Surg 45: 217-223, 1997.
28. Börgermann J, Friedrich I, Feldt T, Reidemeister JC, Schade FU: Evidence of a circulating cytokine synthesis inhibitor during cardiopulmonary bypass. Shock 7:403, 1997.
29. Ayala A, Lehman DL, Herdon CD, Chaudry IH: Mechanism of enhanced susceptibility to sepsis following hemorrhage. Interleukin-10 suppression of T-cell response is mediated by eicosanoid-induced interleukin-4 release. Arch Surg 129:1172-1178, 1994.
30. Flach R, Majetschak M, Heukamp T, Jennissen V, Flohé S, Börgermann J, Obertacke U, Schade FU: Relation of ex vivo stimulated cytokine synthesis to posttraumatic sepsis. Cytokine, 1998 in press.
31. Döcke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W: Monocyte deactivation in sepsis patients: restoration by IFNγ treatment. Nat Med 3:678-681, 1997.
32. Cannistra SA, Vellenga E, Groshek P, Rambaldi A, Griffin JD: Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood 73: 672-676, 1988.
33. Hayes MP, Zoon KC: Priming of human monocytes for enhanced lipopolysaccharide responses: expression of alpha interferon, interferon regulatory factors, and tumor necrosis factor. Infect Immun 61:3222-3227, 1993.
34. Wing EJ, Magee DM, Whiteside TL, Kaplan SS, Shaduck RK: Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor and interferon in cancer patients. Blood 73:643-646, 1989.
35. Lindemann A, Riedel D, Oster W, Ziegler-Heitbrock HWL, Mertelsmann R, Herrmann F: granulocyte-macrophage colony-stimulating factor indues cytokine secretion by human polymorphonuclear leukocytes. J Clin Invest 83:1308-1312, 1989.
36. Han J, Thompson P, Beutler B: Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at seperate points in signaling pathway. J Exp Med 172:391-394, 1990.
37. Fischer HG, Frosch S, Reske K, Reske-Kunz AB: granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHCII molecules and to augment antigen presentation function. J Immunol 141:3882-3888, 1988.
38. Livingston DH, Appel SH, Wellhausen SR, Sonnenfeld G, Polk HC: Depressed interferon gamma production and monocyte HLA-DR expression after severe injury. Arch Surg 123:1309-1312, 1988.
39. 2. J Exp Med 180:2365-2370, 1994.
40. Sherry RM, Cue JI, Goddard JK, Parramore JB, DiPiro JT: Interleukin-10 is associated with the development of sepsis in trauma patients. J Trauma 40:613-616, 1996.
41. Volk HD, Reinke P, Krausch D, Zuckermann H, Asadullah K, Muller JM, Döcke WD, Kox WJ: Monocyte deactivation: rationale for a new therapeutic strategy in sepsis. Intensive Care Med 22 Suppl 4:S474-81, 1996.
42. Ertel W, Morrison MH, Ayala A, Chaudry IH: Eicosanoids regulate tumor necrosis factor synthesis after hemorrhage in vitro and in vivo. J Trauma 31:609-615, 1991.
43. Vial T, Descotes J: Clinical toxicity of cytokines used as haemopoietic growth factors. Drug Saf 13:371-406, 1995.